A panelist discusses how the highest unmet needs in acute myeloid leukemia include treatments for patients with refractory ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase ...

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making immediate treatment essential.

First patient dosed with Debiopharm’s first-in-class CD37 targeted antibody drug conjugate (ADC) in a Phase 1/2, multicenter, open-label trial, for patients with acute myeloid leukemia (AML ...

Learn more about secondary acute myeloid leukemia, including what to expect after diagnosis, how to take care of yourself, and how to find support.

FDA Grants Priority Review To Syndax's Revuforj For R/R MNPM1 Acute Myeloid Leukemia Treatment June 24, 2025 — 09:49 pm EDT Written by RTTNews.com for RTTNews -> ...

Recent progress in the molecular genetics of acute myeloid leukemia (AML) has shown this disease to be more heterogeneous than previously realized. Recurrent cytogenetic and mutational changes in ...

CERo Therapeutics Gets Orphan Drug Status For CER-1236 In Acute Myeloid Leukemia June 17, 2025 — 08:33 am EDT Written by RTTNews.com for RTTNews -> ...

A recent study has revealed promising targets for treating childhood acute myeloid leukaemia (AML) driven by NUP98 fusion ...

About Mutant NPM1 (mNPM1) Acute Myeloid Leukemia (AML) Mutations in the NPM1 gene are the most common genetic alteration observed in adults with AML, occurring in approximately 30% of cases.

Daunorubicin dose intensification has benefits in select patients with acute myeloid leukemia.